Adagio Medical Holdings Inc(ADGM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.44 | Insider Own | 1.22% | Shs Outstand | 27.4M | Perf Week | -10.03% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | -6.42% | Insider Trans | - | Shs Float | 27.1M | Perf Month | -43.17% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.25 | Inst Own | 54.93% | Short Float | 0.49% | Perf Quarter | -89.13% |
| Income | -0.03B | P/S | - | EPS this Y | 27.81% | Inst Trans | -2.42% | Short Ratio | 0.01 | Perf Half Y | -90.75% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 4.3% | ROA | -77.8% | Short Interest | 0.13M | Perf YTD | -91.63% |
| Book/sh | -0.02 | P/C | 0.31 | EPS past 3/5Y | 63.65% -364.47% | ROE | -657.76% | 52W High | -94.85% ($1.69) | Perf Year | -92.37% |
| Cash/sh | 0.28 | P/FCF | - | Sales past 3/5Y | - | ROIC | -107.02% | 52W Low | 7.41% ($0.08) | Perf 3Y | -99.2% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 70.33% | Gross Margin | - | Volatility(W/M) | 19.53% 16.59% | Perf 5Y | -99.13% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.03 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.15 | EPS Q/Q | 13.45% | Profit Margin | - | RSI (14) | 27.5 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.41 | Sales Q/Q | - | SMA20 | -21.21% ($0.11) | Beta | 0.06 | Target Price | $3.33 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/11 | SMA50 | -70.77% ($0.31) | Rel Volume | 0.03 | Prev Close | $0.08 |
| Employees | 41 | LT Debt/Eq | - | EPS/Sales Surpr. | -11.11% - | SMA200 | -88.36% ($0.77) | Avg Volume(3M) | 9.55M | Price | $0.09 |
| IPO | 2021/2/26 | Option/Short | No/Yes | Trades | 220 | Volume | 276,957 | Change | 4.82% |
Adagio Medical Holdings () is a medical device company developing ultra-low temperature cryoablation (ULTC) technology for treating arrhythmias, including ventricular tachycardia (VT). Its flagship vCLAS system received FDA Breakthrough Device Designation and has completed enrollment in the U.S. FULCRUM-VT clinical trial.
Over the past 1 year, on the lower side
95% below its 1-year high.
Traded less than usual. That is 3% of its average volume.
ADGM has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +27.8% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.1%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 54.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #135 of 140 in the industry
Based on market cap of $2M.
NUWE#134 Nuwellis Inc $3M PER - ADGM#135 Adagio Medical Holdings Inc $2M PER - 
BJDX#136 Bluejay Diagnostics Inc $2M PER - 
POAS#137 Phaos Technology (Cayman) Holdings Ltd $2M PER - 
IVF#138 INVO Fertility Inc $2M PER - 
FAQ
What kind of company is ADGM?
ADGM belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of ADGM?
The market cap of ADGM is approximately $2M, ranking 5,772 within its sector.
What is the 52-week high and low for ADGM?
ADGM has recorded a 52-week high of $1.69 and a low of $0.08.
